Akero Therapeutics, Inc.
Akero Therapeutics, Inc. (AKRO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
akro · stock forecast · 14 analysts (3M) · FMP · updated Feb 3, 2026
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Buy
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$56.00
Consensus
$48.40
-11.4% upside
Low
$38.00
Median: $54 · Last Close: $54.65
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$48.40
-11.4% upside
High Target
$56
2.5%
Low Target
$38
-30.5%
Current Price
$54.65
as of today
Based on analyst price targets, the AKRO stock price prediction for the next 12 months ranges from $38 to $56. The consensus AKRO price forecast of $48.40 implies -11.4% upside from the current price of $54.65.
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $54.76 | ↑ 0.20% |
1-day model range: $54.74–$54.78. Peak: $54.78 (+0.20%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AKRO · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-10-10 | Wolfe Research | Downgrade ↓ | Outperform→Peer Perform |
| 2025-10-10 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-10-09 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2025-10-09 | Canaccord Genuity | Downgrade ↓ | Buy→Hold |
| 2025-05-27 | B of A Securities | Maintains | Buy→Buy |
| 2025-05-13 | Citigroup | Maintains | Buy→Buy |
| 2025-03-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-31 | UBS | Maintains | Buy→Buy |
| 2025-01-30 | B of A Securities | Upgrade ↑ | Neutral→Buy |
| 2025-01-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Akero Therapeutics, Inc. (AKRO) stock. Of the recent 63 rating actions, 3 were upgrades and 5 were downgrades. 14 analysts currently cover AKRO.
Analyst Recommendation Trends
AKRO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$3M
EPS This Year
$-3.82
EPS Next Year
$-4.31
↑ 13.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast AKRO EPS of $-3.82 for the current fiscal year, based on estimates from 4 analysts. The AKRO revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AKRO stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AKRO price target is $48.40 (-11.4% upside), with an analyst consensus of Buy.
The AKRO short-term stock prediction for tomorrow is $54.76 (+0.20%).
Akero Therapeutics, Inc. trades on NASDAQ under the ticker AKRO. The AKRO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.
Frequently asked questions
AKRO forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month AKRO price target is $48.40, with a high forecast of $56.00 and a low of $38.00. The median price target is shown in the chart above when available. This implies -11.4% potential upside from the current price of $54.65.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.